Genscript Biotech Corporation
1548
Κατάταξη σε μετοχές
#2088
Operating as an investment holding company, Genscript Biotech Corporation,... Operating as an investment holding company, Genscript Biotech Corporation, established in 2002 and headquartered in Nanjing, People's Republic of China, specializes in the global provision of innovative life science research solutions, encompassing both products and services. Its market presence spans North America, Europe, China, Japan, other Asia Pacific regions, and numerous international markets. The enterprise structures its operations into four key divisions: The Life Science Services and Products segment delivers a wide array of research offerings, such as gene and oligonucleotide synthesis, molecular cloning, protein and peptide engineering, antibody production, molecular diagnostic instruments, and genomic editing materials. These resources are instrumental for fundamental biological investigations, pharmaceutical and drug discovery, disease diagnostics, vaccine development, and applications in agriculture, environmental science, and food production. The Biologics Development Services division supports pharmaceutical, biotechnology, governmental, and academic institutions. It provides comprehensive services for the full lifecycle of therapeutic antibodies, from initial discovery through pre-clinical and clinical development, alongside pre-clinical and clinical development for plasmids and viruses, and broader gene and cell therapy development. Dedicated to industrial applications, the Industrial Synthetic Biology Products segment engineers non-pathogenic microbial strains and manufactures specialized enzymes. These enzymes find utility across the food processing, animal feed, pharmaceutical, and chemical sectors. Finally, the Cell Therapy unit focuses on the pioneering discovery and advanced development of chimeric antigen receptor T-cell (CAR-T) therapies, specifically designed to combat both liquid and solid malignant tumors.
Τιμή μετοχής
$4.24
Κεφαλαιοποίηση
$9.53B
Αλλαγή (1 ημέρα)
-3.15%
Αλλαγή (1 έτος)
104.85%
Χώρα
HK
Εμπόριο Genscript Biotech Corporation (1548)
Κατηγορία
Healthcare
Έσοδα για την Genscript Biotech Corporation (1548)
Έσοδα τον Jun 2026 TTM: $844.00M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Genscript Biotech Corporation, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι $844.00M. Το 2023, η εταιρεία είχε έσοδα $839.53M αύξηση σε σχέση με τα έσοδα του έτους 2022, τα οποία ήταν $625.70M. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Genscript Biotech Corporation από 2013 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $844.00M | 41.97% |
| 2024 | $594.49M | -29.19% |
| 2023 | $839.53M | 34.17% |
| 2022 | $625.70M | 27.67% |
| 2021 | $490.10M | 25.39% |
| 2020 | $390.85M | 42.98% |
| 2019 | $273.35M | 18.33% |
| 2018 | $231.02M | 51.34% |
| 2017 | $152.65M | 33.04% |
| 2016 | $114.74M | 32.32% |
| 2015 | $86.71M | 23.88% |
| 2014 | $69.99M | 16.45% |
| 2013 | $60.10M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $12.62B | 1,395.77% |
US
|
|
| $2.23B | 163.98% |
US
|
|
| $15.74B | 1,765.44% |
AU
|
|
| $6.02B | 613.42% |
NL
|
|
| - | - |
CH
|
